**Author details**

Julie B. McLean, Nigeste Carter, Payal Sohoni and Mark A. Moore\* LifeNet Health, Virginia Beach, VA, USA

\*Address all correspondence to: mark\_moore@lifenethealth.org

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**43**

*Cell Attachment and Osteoinductive Properties of Tissue Engineered, Demineralized Bone Fibers…*

with autograft. Spine (Phila Pa 1976).

[10] McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). Journal of Spinal Disorders and Techniques. 2006;**19**(7):483-486

[11] Lewandrowski KU, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: A report of five cases. The Spine Journal.

[12] James CDT. Sir William Macewen. Proceedings of the Royal Society of Medicine. 1974;**67**(4):237-242

[13] de Boer HH. The history of bone grafts. Clinical Orthopaedics and Related Research. 1988;**226**:292-298

[14] Zimmermann G, Moghaddam A. Allograft bone matrix versus synthetic

[15] Miller LE, Block JE. Safety and effectiveness of bone allografts in anterior cervical discectomy and fusion surgery. Spine (Phila Pa 1976).

[16] Senn N. On the healing of aseptic bone cavities by implantation of antiseptic decalcified bone. The American Journal of the Medical Sciences.

[17] Urist MR, Strates BS. The classic: Bone morphogenetic protein. Clinical Orthopaedics and Related Research.

Einhorn TA. The role of growth factors

bone graft substitutes. Injury.

2011;**42**:S16-S21

1889;**98**:219-243

2011;**36**(24):2045-2050

2009;**467**(12):3051-3062

[18] Lieberman JR, Daluiski A,

2006;**31**(7):775-781

2007;**7**(5):609-614

*DOI: http://dx.doi.org/10.5772/intechopen.88290*

[1] Khan WS, Rayan F, Dhinsa BS, Marsh D. An osteoconductive, osteoinductive, and osteogenic tissue-engineered product for trauma and orthopaedic surgery: How far are we? Stem Cells International. 2012;**2012**:236231

[2] Wang W, Yeung KWK. Bone grafts and biomaterials substitutes for bone defect repair: A review. Bioactive Materials. 2017;**2**(4):224-247

[3] Oommen AT, Krishnamoorthy VP, Poonnoose PM, Korula RJ. Fate of bone grafting for acetabular defects in total hip replacement. Indian Journal of Orthopaedics. 2015;**49**(2):181-186

[4] Younger EM, Chapman MW. Morbidity at bone graft donor sites. Journal of Orthopaedic Trauma.

[5] Park SB, Chung CK. Strategies of spinal fusion on osteoporotic spine. Journal of Korean Neurosurgical Association. 2011;**49**(6):317-322

[6] Lobb DC, DeGeorge BR Jr, Chhabra AB. Bone graft substitutes: Current concepts and future expectations. The Journal of Hand Surgery. 2019;**44**(6):497-505.e2

[7] Klifto CS, Gandi SD, Sapienza A. Bone graft options in upper-extremity surgery. The Journal of Hand Surgery.

[8] Fernandez de Grado G, Keller L, Idoux-Gillet Y, Wagner Q , Musset A-M, Benkirane-Jessel N, et al. Bone substitutes: A review of their characteristics, clinical use, and perspectives for large bone defects management. Journal of Tissue

[9] Burkus JK, Sandhu HS, Gornet MF. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison

2018;**43**(8):755-761.e2

Engineering. 2018;**9**:1-18

1989;**3**(3):192-195

**References**

*Cell Attachment and Osteoinductive Properties of Tissue Engineered, Demineralized Bone Fibers… DOI: http://dx.doi.org/10.5772/intechopen.88290*
